Navigation Links
Aida Receives Chinese Government Innovation Award
Date:1/7/2008

SANTA MONICA, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced that it has received an award from the Science and Technology Department of Zhejiang Province, one of the richest regions in China and known throughout the country for its focus on innovation. Aida was rewarded by the governmental authority because of its "clinical research and commercialization of Rh-Apo2L" as a "significant scientific and social developing project" recognized by the Science and Technology Department of Zhejiang Province. The Science and Technology Department of Zhejiang Province is the governmental administrative department for the entire science and technology industry in Zhejiang Province.

Mr. Jin Biao, Chairman of Aida Pharmaceuticals, stated, "We are very honored to have this major award bestowed on us by the Science and Technology Department of Zheijiang Province. The government has supported our efforts throughout Rh-Apo2L's development process." The award also includes a financial reward, totaling RMB1.2 million (US$164,982.47, as of January 2008).

About Aida Pharmaceuticals

Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. The Company has nine product lines including its main product, Etimicin Sulfate, the first antibiotic developed in China, which it manufactures and markets in powder, liquid and transfusion form. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995

With the exception of historical information, the matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of Aida Pharmaceuticals could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations, inability to hire and retain qualified personnel, and changes in the general economic climate. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by Aida Pharmaceuticals, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.


'/>"/>
SOURCE Aida Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Three Palm Software Receives FDA 510(k) Clearance for Its WorkstationOne(TM) Breast Imaging Workstation
2. Genta Receives NASDAQ Non-Compliance Notice
3. Tapestry Receives Notice Regarding Minimum Bid Price Rule
4. CleveMed Receives $1.5 Million in NIH Funding to Further Develop a Portable System for Monitoring Parkinsons Disease Motor Symptoms
5. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
6. Nonin Medical, Inc. Receives Frost & Sullivans 2007 Award for Product Differentiation Innovation
7. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
8. Biomerica Introduces a New 15 Minute Home Test for Allergies to Cats and Receives CE Mark Approval for Home Use
9. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer
11. Healthcare Technologies, Ltd. Receives Notice From Nasdaq
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... NEW YORK , January 20, 2017 ... Health Organization, cancer is one of leading causes of ... in 2012. Although the number of cancer related deaths ... since 1990. Rising in incidence rate of various cancers ... According to a research report by Global Market Insights, ...
(Date:1/19/2017)... Research and Markets has announced the addition ... Type, Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" ... ... is projected to reach $15,737 million by 2022 from $6,521 in ... Omic technologies segment accounted for more than half ...
(Date:1/19/2017)... HOUSTON , Jan. 19, 2017 /PRNewswire/ ... the formation of its Medical/Clinical Advisory Board.  This ... veterans who enhance the range and depth of ... of its novel prenatal diagnostic tests.  These experts ... strategic guidance for the company,s product development and ...
(Date:1/19/2017)... Jan 19, 2017 Research and Markets ... has announced the addition of the ... - Forecast to 2025" report to their offering. ... The report provides a detailed analysis on current and future market ... 2025, using estimated market values as the base numbers ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in mobile ... market" The mobile biometrics market is expected to grow ... billion by 2022, at a CAGR of 29.3% between ... such as the growing demand for smart devices, government ... "Software component is expected to grow at ...
(Date:12/8/2016)... -- Singulex, Inc., the leader in Next Generation Immunodiagnostics powered ... and supply agreement with Thermo Fisher Scientific, the world ... to Thermo Scientific BRAHMS PCT (Procalcitonin), a biomarker which, ... diagnose systemic bacterial infection and sepsis and in ... assessing the risk of critically ill patients for progression ...
(Date:12/7/2016)... , Dec. 7, 2016   Avanade is ... Formula One teams in history, exploit biometric data in ... performance and maintain the competitive edge against their rivals ... Avanade has worked with Williams during ... of biometric data (heart rate, breathing rate, temperature and ...
Breaking Biology News(10 mins):